

Antiviral therapy prolongs survival in immune tolerant hepatitis B patients

April 15 2016

A new study, presented today at The International Liver Congress 2016 in Barcelona Spain, demonstrates that the use of antiviral therapy for patients in the immune tolerant phase of Hepatitis B (HBV) prolongs overall survival and reduces the risk of the most common form of liver cancer (Hepatocellular Carcinoma, HCC) and scarring of the liver (cirrhosis).

The study showed that the risks of developing HCC and [liver cirrhosis](#) were significantly lowered among those who received nucleos(t)ide analogue treatment.

Hepatitis B is the most common serious [liver infection](#) in the world. It is caused as the virus, transmitted through blood and infected bodily fluids, attacks the [liver](#).¹ In the immune tolerant stage, HBV actively replicates in the liver, but remains unrecognised by the immune system. Patients can remain in this stage for decades with high viral load but no apparent damage to the liver.² There are two treatment options for HBV immune tolerant patients: pegylated interferon strategy, or nucleos(t)ide analogues.³

"Our study demonstrates that nucleos(t)ide analogue treatment offers promising results in reducing the risk of [liver cancer](#) and damage among those patients who have limited treatment options," said Professor Jeong-Hoon Lee of the Liver Research Institute at Seoul National University, Korea and corresponding author of the study. "Furthermore, in contrast to the control group who received no treatment during immune tolerant

phase, overall survival was significantly prolonged for those who received nucleos(t)ide analogue treatment."

The single-center retrospective study was conducted in 644 patients diagnosed as HBeAg-positive chronic HBV (an indicator of active viral replication) with alanine aminotransferase levels within two times of upper normal limit, without evidence of liver cirrhosis. Patients were divided into two groups, the group who received [antiviral therapy](#) and the control group who received no therapy until the immune-active phase. The primary endpoint of the study was overall survival and secondary endpoints were the development of HCC and liver cirrhosis.

After balancing for baseline characteristics between the two groups, the risk of developing HCC (Hazard Ratio [HR]= 0.084; 95% Confidence Interval [CI]=0.030-0,234; p

Citation: Antiviral therapy prolongs survival in immune tolerant hepatitis B patients (2016, April 15) retrieved 4 May 2024 from <https://medicalxpress.com/news/2016-04-antiviral-therapy-prolongs-survival-immune.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--